This year's UCHS GI Oncology Retreat, attended by University of Colorado Cancer Center and University of Colorado Health physicians, nurses, staff and specialists, provided the latest information on the strides being made at the CU Cancer Center in pancreatic cancer research and treatments. WINGS OF HOPE founder Maureen Shul was invited to attend and participate in the day long retreat.
Dr. Richard D. Schulick, Professor and Chair of Surgery at the CU Cancer Center, provided the update on pancreatic cancer, which included these statistics:
Today, November 13th, is the first ever WORLD PANCREATIC CANCER DAY. WINGS OF HOPE FOR PANCREATIC CANCER RESEARCH supports every effort to raise awareness of this horrific disease, and invites you to support the local pancreatic cancer research taking place at the University of Colorado Cancer Center. Every dollar raised by WINGS OF HOPE goes to the CU Cancer Center for their pancreatic cancer research with the goal of finding early diagnostic methods, more effective treatments and ultimately a cure.
If you persistently experience one or more of the following symptoms which are not normal for you, do not ignore them! Contact your doctor immediately.
Make a difference and help support WINGS OF HOPE FOR PANCREATIC CANCER RESEARCH in their efforts to raise awareness and funding for the pancreatic cancer research ongoing at the CU Cancer Center.
Denver Post, Your Hub, October 2, 2014
Wings of Hope for Pancreatic Cancer Research presents an evening with author and mountain climber Eric Alexander, who defied all odds and scaled Mt. Everest while guiding his blind friend, Erik Weihenmayer, to its 29,035 foot summit.
The event is Thursday, October 30 at The Wildlife Experience. Doors open at 6:00 pm and will include hors d’oeuvres, drinks, desserts and live auction. Referred to as the most challenging adventure in mountaineering, renowned climber and motivational speaker Eric Alexander will recount his incredible story of hope, perseverance and survival scaling Mt. Everest.
Maureen Shul, former mayor of the City of Castle Pines, founded Wings of Hope in 2012 after losing both her brother and mother to the disease within months of one another.
“Very few people are aware of the tremendous strides being made in pancreatic cancer treatments and research right here at Anschutz Medical Campus,” stated Shul. “It is the mission of this foundation to keep raising awareness and funding for the CU Cancer Center pancreatic cancer research through events such as this one.”
BY GARTH SUNDEM IN HONORS, LATEST NEWS · JUNE 23, 2014
University of Colorado Cancer Center member, Colin Weekes, MD, PhD, was recently accepted into the prestigious American Society for Clinical Oncology (ASCO) Leadership Development Program for years 2014-15. Weekes is an associate professor in the Division of Medical Oncology at the CU School of Medicine with a joint appointment at the Denver Veteran’s Administration Medical Center. He is a member of the University of Colorado Cancer Center Gastrointestinal and Developmental Therapeutics Programs.
“The goal of the program is to train young researchers for leadership positions within ASCO and at their institutions. I’m honored to be included in this class of twelve exciting, young pioneers,” Weekes says.
During the one-year program, ASCO will present participants with a challenge program, which participants will develop and then present to the ASCO Board of Directors at the conclusion of the year. In addition, participants will convene four times throughout the year for formal leadership training. Each year, the competitive application process results in 12 young cancer investigators accepted into the program. Weekes follows CU Cancer Center colleagues Wells A. Messersmith, MD, and Thomas R. Flaig, MD, both of whom completed the program in previous years and both of whom have gone on to lead initiatives within ASCO and the CU Cancer Center.
Weekes hopes that his experience with the program will allow leadership opportunities to promote minority enrollment in clinical trials.
“The barriers to minority enrollment in clinical trials is multifactorial and include Lack of information and access to clinical trials, historical events resulting in distrust in the clinical research process, as well as socioeconomic issues for some patients,” Weekes says. As an example, he points out that for phase 1 clinical trials, patients frequently must spend two or three days per week at the treatment center, which can be challenging in terms of travel costs and lost wages for patients with limited financial resources.
“On a personal level, I just want to gain more leadership skills to be a good leader for the people I work with here at the Center. On a larger scale, I hope to begin to understand how to develop initiatives in cancer care,” Weekes says.
Please join the CU Cancer Center in congratulating Dr. Weekes on his acceptance to this prestigious program, which will connect one of our most promising young researchers with the ability to create change on a national level.
With deep sadness we mourn the loss of Walt Imhoff, Denver financier and philanthropist, and first donor/supporter of WINGS OF HOPE FOR PANCREATIC CANCER RESEARCH.
Walt Imhoff was the first person I reached out to when WINGS OF HOPE was formed. His beloved wife Georgia had lost her battle with pancreatic cancer, and in sharing my own losses to this relentless disease with him, we forged a friendship built on shared grief and a passion to fight back in whatever way we could.
In that first meeting several years ago, Walt Imhoff not only shared his support for WINGS OF HOPE, but his tears as well for all he lost to this disease.
In loving memory of Walt Imhoff and all those impacted by pancreatic cancer, our efforts continue on stronger than ever to fund the pancreatic cancer research ongoing at CU Cancer Center - Anschutz Medical Campus.
Maureen A. Shul
With November being National Pancreatic Cancer Awareness month, it is important to note the progress being made on this disease on the Anschutz Medical Campus.
Since the opening of a multi-disciplinary clinic at the University of Colorado Cancer Center last year, more than 200 pancreatic cancer patients have been seen, giving patients access in one day to every specialist necessary to design a complete and personalized plan of treatment. In that same time, more than 100 pancreatic cancer surgeries have been performed, making the CU Cancer Center a premier destination nationwide for pancreatic cancer care.
The center also participated in the clinical trials that resulted in the recent FDA approval of Abraxane for treatment of pancreatic cancer.
For those of us who have lost loved ones to this horrific disease, it is not enough to have pancreatic cancer mentioned only in obituaries. Awareness of the latest treatments and research taking place right here can make all the difference to patients and family members.
On September 6, 2013, the U.S. Food and Drug Administration approved ABRAXANE® in combination with gemcitabine for the first-line treatment of patients with advanced metastatic pancreatic cancer.
The approval of Abraxane was based on clinical trials involving 861 patients with metastatic pancreatic cancer, the median age of the patients being 63 years.
With no early diagnostic methods or effective treatments for pancreatic cancer, the announcement of this approval was welcomed news for the many impacted by this disease. It has been almost eight years since the last treatment was approved for patients with pancreatic adenocarcinoma, the most common form of pancreatic cancer.
"This treatment approval is extremely important for patients as it represents an incremental improvement in therapy," stated Dr. Colin Weekes, Director, Pancreas Medical Oncology Program, University of Colorado School of Medicine. "This new regimen will serve as a new foundation of combination therapy to which molecular targeted therapies can be added."
WINGS OF HOPE FOR PANCREATIC CANCER RESEARCH is encouraged by this latest advancement in treatments and remains committed to raising awareness and funding for the ongoing pancreatic cancer research at the University of Colorado Cancer Center.
WINGS OF HOPE joined 45 other cancer-related non-profits at the 5th Annual Step Up For Cancer event held at Dick's Sporting Goods Stadium in Commerce City.
Under a perfect and sunny early morning sky, close to 1,000 participants raced, ran and walked the 1735 stadium steps. Others chose to walk the perimeter of the soccer field and some came to cheer on their friends and family members while learning more about the many non-profit organizations involved in cancer awareness, treatment, care and research.
The event was for all ages, from small kids climbing the stadium steps to retirees keeping up with them, some never breaking a sweat.
WINGS OF HOPE will be a participant again next year, organizing teams of supporters to represent and raise funds for WINGS OF HOPE.
Virginia Grantier firstname.lastname@example.org | Posted: Sunday, August 18, 2013 4:30 pm
A foundation started by Castle Pines' first mayor, Maureen Shul, recently gave a $45,000 check to the University of Colorado Cancer Center to help support pancreatic cancer research.
Shul lost her mother and brother to pancreatic cancer within months of each other and later established a foundation called Wings of Hope for Pancreatic Cancer Research.
"Wings of Hope is committed to raising awareness of the pancreatic cancer research and treatments taking place at the CU Cancer Center," said Shul. "We are also committed to making sure people know the specific pancreatic cancer research programs their donations are helping to support." She said the money was raised at an April event at Parker's The Wildlife Experience, where her brother, Brian Shul, a U.S. Air Force pilot, had been a guest speaker.
“We had a sell-out event, which resulted in our being able to present $45,000 to the University of Colorado Cancer Center,” she said. But that's not the end. “We are working on our next events, one of which will include climbing a 'fourteener' to raise funds,” she said. Dr. Colin Weekes, who accepted the check, is an oncologist and an investigator at the cancer center.
Weekes said currently there are few treatment options for these patients. The donation will be used to advance the development of targeted therapies by identifying the genetic biomarkers in pancreatic cancer tumors.
"The donation from Wings of Hope will help us advance the discovery and development of therapies that may improve the outlook for people diagnosed with this type of cancer."
Shul, who led the effort to incorporate Castle Pines, was elected its first mayor in 2007 and served as mayor and then on council until 2012. Pancreatic cancer is the fourth leading cause of cancer deaths in the United States and is projected to rise to the second leading cause by 2020, according to information from Shul. It is estimated that 43,000 Americans are diagnosed each year with pancreatic cancer, with 74 percent not surviving beyond 12 months.
Photos taken by Lynn Hillenburg Zahorik
Warmest thanks to all those who made purchases at Tagawa Gardens through their Give Back Program this past month to help WINGS OF HOPE. A percentage of all the sales made during this time period that mentioned WINGS OF HOPE will be shared with the foundation in the coming weeks.
Your continued support is so important and appreciated! And we hope your gardens are flourishing!
Based in Telluride, BIG COLORADO LOVE makes hats, shirts, stickers, and other popular items, donating 10% of their profits to Colorado charities. Their selection of WINGS OF HOPE was in memory of Tamara Guttman Theemling who fought pancreatic cancer for over 3 years before passing away in 2012. The model of a Colorado mountain woman, Tamara lived, loved and explored the mountains and rivers of Colorado in every way she could, and is deeply missed by her many friends and family.
Your purchasing items from BIG COLORADO LOVE (www.bigcoloradolove.com) through June will help support WINGS OF HOPE. In turn, your liking them on Facebook and spreading the word will help support BIG COLORADO LOVE.
By Chris Michlewicz
Maureen Shul was riding high as the first mayor of Castle Pines when her life came crashing down.
It wasn’t a political scandal that forever altered her career path and, ultimately, the course of her life. It was the consecutive losses of two of her staunchest supporters: her brother and mother. And their deaths were attributed to the same illness.
Shul admits that she didn’t even know what a pancreas was, let alone her unfamiliarity with the aggressive nature of the cancer that infiltrates the internal organ. Her family does not have a history of cancer, and there were no warning signs before her brother, Victor, was diagnosed in 2005.
His was something of a rare story; he battled for four years before passing away in 2009. Others are taken suddenly, as was the case with Shul’s mother, who survived only three months after her August 2009 diagnosis.
“The losses were so profound and so great, I had to steady myself and learn how to keep going,” she said.
Shul coped, in part, by joining national efforts to raise money for pancreatic cancer research. Then she learned that intensive research was occurring in the Denver area, and immediately shifted her focus. She created Wings of Hope for Pancreatic Cancer Research , her own nonprofit foundation, and in February partnered with those Denver researchers.
Doctors and scientists at the University of Colorado Cancer Center at the Anschutz Medical Campus are engaged in multi-pronged studies to try and determine the cause of pancreatic cancer, the most effective treatment methods and ways to detect it much earlier.
The first fundraiser for Wings of Hope, scheduled for April 25 at The Wildlife Experience, is nearly sold out, reflecting the high number of people in Douglas County with a great interest in stopping the disease’s advance. The best part is that Shul and the nonprofit’s board of directors will have direct discussion with researchers to determine the best use of the funds that are raised.
“Of all of the things I’ve ever been involved with, nothing has been more meaningful or significant as starting this foundation,” Shul said.
The charity event will not only highlight advances in research and raise awareness, it will feature Shul’s brother, Brian, a bestselling author and former SR-71 pilot, as the keynote speaker. Brian Shul will relate his harrowing story of survival after being shot down over Vietnam. His family received notification that he died, and it wasn’t until 48 hours later that they learned he was alive.
When asked what her brother and mother would think about her actions in the wake of their untimely deaths, Shul says she hopes they would be proud
“We’re making a contribution in a way that is honoring them as well as helping me get through all of this,” she said. “I’m doing what I’m supposed to be doing. I couldn’t just walk away from it.”
AURORA, Colo. ( Jan. 29, 2012) - University of Colorado Cancer Center and Wings of Hope for Pancreatic Cancer Research have joined forces to raise awareness about pancreatic cancer and boost funding for pancreatic cancer research and related CU Cancer Center programs.
“We are happy to partner with Wings of Hope in our efforts to find effective therapies for those with pancreatic cancer,” says Colin Weekes, MD, PhD, medical oncologist and member of the CU Cancer Center.
Pancreatic cancer is the 4th leading cause of cancer death in the United States and is projected to rise to the 2nd leading cause by 2020. It is estimated that 43,000 Americans are diagnosed each year with pancreatic cancer, 74 percent will not survive longer than 12 months.
“In terms of the magnitude of human suffering it causes, pancreatic cancer is underfunded and this collaboration will help us address this” says Dan Theodorescu, MD, PhD, Director of the CU Cancer Center.
“There is no broadly accepted early detection method for pancreatic cancer and effective treatments are limited. But we hope to improve the outlook for people with pancreatic cancer by discovering and developing biologically targeted therapies,” Weekes says.
Wings of Hope was founded in February of 2012 by Maureen Shul, the former mayor of Castle Pines, after she lost two family members to pancreatic cancer. Wings of Hope is dedicated to supporting research and clinical care at CU Cancer Center.
“The pancreatic cancer research and treatment taking place at CU Cancer Center is second to none and it is a privilege to have Wings of Hope a focused part of the effort to raise awareness as well as funding for this incredibly important work,” says Shul.
After being passed by Congress in December 2012, the RECALCITRANT CANCER RESEARCH ACT was signed into law by President Obama on January 3, 2013.
This legislation, attached to the National Defense Authorization Act, requires the National Cancer Institute (NCI) to examine its current research efforts on cancers with very low survival rates and work to develop early detection methods and better treatment options to help improve outcomes for those diagnosed with the most deadly forms of cancer, including pancreatic and lung cancer.
As the first legislation to specifically include and focus on pancreatic cancer, the NCI will be required to establish scientific frameworks for pancreatic and other deadly cancers including rigorous evaluations of existing research efforts and the progress being made in the prevention, detection, diagnosis and treatment of these deadly cancers.
Realizing the critical importance of this legislation in the advancement of specific and focused research, WINGS OF HOPE for PANCREATIC CANCER RESEARCH is dedicated to raising awareness and funding for the cutting edge research, clinical trials and treatments currently ongoing at the University of Colorado Cancer Center’s Pancreatic Cancer Research Program.
Below is a commentary written by Maureen Shul for the Denver Post on 11/4/2012.
November is National Pancreatic Cancer Awareness Month. For most, that may be the only time they hear about pancreatic cancer. For too many others, it will be one more heart breaking reminder of a devastating disease that family and friends have been lost to.
When my brother was diagnosed with pancreatic cancer, I readily admit I had no knowledge of what a pancreas was, what it did and what it meant to have cancer there. No amount of research softened the statistics. Only two out of ten people with pancreatic cancer survive beyond one year after being diagnosed, and fewer than six percent will survive beyond five years. That survival rate has not changed in the last 40 years.
I expanded my research to the most well known medical institutions throughout the country, all confirming what I knew but did not want to believe. Pancreatic cancer has no known cause, no early detection methods, no effective treatments and no cure. By the time someone is diagnosed, it is almost always too late for any type of effective treatment.
My brother was as strong, healthy and courageous as they come, but he was no match for a disease that came with no warning and remained relentless in its horrific grasp. His suffering and fight lasted four years.
Three months after losing my brother, my mother was diagnosed with pancreatic cancer. She died ninety devastating days later.
While in the midst of grief from such profound losses, I met one of the physicians from the University of Colorado Cancer Center specializing in pancreatic cancer. It was a revelation to learn that the University of Colorado’s Pancreatic Cancer Research Program boasts and continues to attract an elite group of physicians specializing in the research and treatment of pancreatic cancer. What sets their work apart from others is their multi-disciplinary approach to patient treatment, exemplified by the personalized and focused treatment plan developed for each patient by a team of physicians representing the disciplines of medical oncology, surgical oncology, radiation oncology, pathology, radiology and interventional gastroenterology.
Their goal is nothing short of developing a leading national academic pancreatic cancer research program here at the University of Colorado Anschutz Medical Campus, and they are well on their way. Cutting edge research, access to the most advanced treatments, highest levels of patient care and extensive clinical trials are all taking place right now and right here.
To help raise awareness for the focused ongoing efforts at the University of Colorado Cancer Center’s Pancreatic Cancer Research Program, the Wings of Hope for Pancreatic Cancer Research Foundation was formed earlier this year.
Pancreatic cancer is currently the 4th leading cause of cancer death in the United States. By 2020, it is anticipated pancreatic cancer will become the 2nd leading cause of cancer death in the United States. We have the opportunity right now to help change that projection by supporting the efforts and strides being made in our own back yard.
A leading medical institution in Texas recently announced a “moon shot” effort against eight specific forms of cancer, akin to the all out effort for landing a man on the moon 50 years ago. Pancreatic cancer was not included among the eight cancers. The time is now for pancreatic cancer to be brought out into the open, to where it will no longer be the most underfunded and least studied among the major cancers.
We can be stunned by statistics and numbed by grief, but we must not stand by while this disease expands its devastating reach.
The dedicated physicians at the University of Colorado Cancer Center’s Pancreatic Cancer Research Program are not giving up on their goal to have their program second to none in the fight against pancreatic cancer.
And neither should we.
Maureen A. Shul, former mayor of Castle Pines, is founder of Wings of Hope for Pancreatic Cancer Research.
Below is a commentary written by Maureen Shul for the Denver Post on 10/08/2011.
Pancreatic cancer was in the news this week for all the reasons we dread most.
Scientist Ralph Steinman died from pancreatic cancer just three days before the announcement was made that he had won the Nobel Prize for medicine. A pioneer in understanding how cells fight disease, Steinman was using his own research and discoveries in his battle with pancreatic cancer.
The passing of Steve Jobs from a rare form of pancreatic cancer (pancreatic neuroendocrine tumor) devastated everyone who believed that if anyone could beat the odds, he could. That he fought for nearly eight years upon being diagnosed with this rare form of cancer and still managed to remain at the forefront of altering our culture and technology is a testament to the fight he endured.
These two most recent public deaths involving pancreatic cancer are a stark reminder of the severity of this deadly disease.
It becomes easy to understand why races and walks comprised of pancreatic cancer survivors who beat the disease will not take place anytime soon.
The five-year survival rate for pancreatic cancer is only 6 percent. For 40 years, this survival rate has remained in the single digits, despite the increase in those being diagnosed, and despite the fact that it is the fourth-leading cause of cancer death. This year, 44,000 Americans will be diagnosed with pancreatic cancer. Of those, close to 38,000 will die from the disease.
There are no conclusive tests for early diagnosis, there are no effective treatments, and there is no cure.
Pancreatic cancer is the most underfunded, under-recognized and least studied of all major cancer killers, receiving only 2 percent of the National Cancer Institute's research budget. That scientist Steinman was using his own research in his battle with pancreatic cancer provides heartbreaking insight into how slim the arsenal is in fighting this disease. As breast cancer was years ago, pancreatic cancer remains in the shadows when it comes to awareness and research funding, a fact that cuts through the hearts of those who have lost loved ones to this horrific disease
While legislation is pending before Congress that will implement better targeted research, the national Pancreatic Cancer Action Network continues investing in a research strategy that will advance early diagnostics, more effective treatments and increase chances of survival.
In mid-2009, I lost my brother to pancreatic cancer after his four-year battle with a disease that proved relentless in its tortuous power. Several months after he died, my mother was diagnosed with pancreatic cancer and passed away three months later.
After losses this profound and close to each other, it is almost as if you must learn how to walk and breathe all over again. But there comes a moment in the midst of grief where you are compelled to do something, for the loved ones lost, and for those who have been, who are or who will be forced on that same dark journey.
In honor of my mother and brother, I am organizing a benefit to help raise awareness and increased research funding for pancreatic cancer. The Wings of Hope benefit will be held Oct. 22 at Wings Over The Rockies Air & Space Museum. For more information, go to pancan.org/wingsofhope.
As pancreatic cancer continues its steady and shattering assault on families, we must make it a national priority and give patients a fighting chance. The statistics can and must change.
There come events in our lives that demand of us more than being a bystander in the bleachers doing nothing. This is that moment, for all of us.
Below is a commentary written by Melanie Avner for the Denver Post on 11/08/2011.
When Carnegie Mellon Professor Randy Pausch gave his unforgettable "Last Lecture," and publicly shared his battle with pancreatic cancer, my heart ached for him, his wife and his three beautiful children. I knew the statistics, and I knew pancreatic cancer was horrendous, scary and devastating. What I didn't know then — what none of us knew — was that the very same cancer was spreading in my mother's body.
One week before my mother received the news that she had a mass on her pancreas, she started to feel unwell, just not herself. But what puzzled and alarmed her most was the severe itching in her hands and feet. She also mentioned the strange color of her urine.
Prior to these symptoms, which came on suddenly, she felt fine. In fact, she was the picture of health. My mother, who was 63, ate right, exercised and always knew the latest cancer research and findings. She took care of herself.
She, too, knew about pancreatic cancer long before it changed her life. Though she no longer worked in a hospital, my mother was a registered nurse. So when she got that call on April 17 with the results of her CT scan, the first words that came to her mind were: "death sentence."
My mother had that reaction because the statistics are grim. According to the Pancreatic Cancer Action Network, an advocacy group that works to raise funds and awareness to fight pancreatic cancer, the five-year survival rate for pancreatic cancer is less than 5 percent, making it the most lethal cancer in the United States. In most cases — nearly 90 percent — the disease has already metastasized before it is diagnosed, ruling out surgery, which is the best hope for long-term control of the disease.
By the time my mother exhibited symptoms, the cancer had already spread to her liver. Surgery to remove the tumor was not an option. Just two weeks after she began to feel ill, my mother was diagnosed with stage IV pancreatic cancer and told she likely had less than a year to live.
Pancreatic cancer is the fourth-leading cause of cancer death in the United States. The Pancreatic Cancer Action Network reports that in 2008, more than 38,000 Americans will be diagnosed with pancreatic cancer and nearly 34,000 will die. The survival rate has remained largely unchanged in the last 30 years.
Pancreatic cancer research constitutes less than 2 percent of the National Cancer Institute's federal research funding — a figure far too low given the severity of the disease. From a scientific research perspective, pancreatic cancer is where breast cancer was in the 1930s. Advancing pancreatic cancer research into the 21st century is dependent upon the increase of basic scientific research.
November is Pancreatic Cancer Awareness Month. I wish my mother could have lived to see that such a month even existed. She died on Aug. 20, just four months after her diagnosis. Four months. Four months from diagnosis to death. That is pancreatic cancer.
It would have been understandable for me to say that I never wanted to see, speak or hear about pancreatic cancer again after the devastation and pain that it caused my family. And I'm sure many others have felt exactly the same. That is probably what happens far too often.
But we cannot continue to turn our backs on pancreatic cancer. As terrifying as it is to face straight on, we must. We must demand more funding for research, better screening and detection, improved treatments, and increased education and awareness. The Pancreatic Cancer Action Network has made significant strides, but unfortunately, there is a long road ahead.
As Pausch said several months before he died, "Pancreatic cancer is disorienting, it's frightening, it's horrifying. The way you beat it is you give a lot of smart people the funding to do their job." I hope you'll join me in doing just that. You'll be creating hope for those courageous individuals who are living with pancreatic cancer and honoring those we have lost to this terrible disease.
JOIN THE EFFORT…BE A PART OF THE POSSIBLE, BE THE HOPE.